TACE combined with liver resection versus liver resection alone in the treatment of resectable HCC: a meta-analysis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-11

AUTHORS

Tingting Yu, Ximing Xu, Biao Chen

ABSTRACT

ObjectiveThe efficacy of preoperative transarterial chemoembolization (TACE) for hepatectomy on hepatocelluar carcinoma (HCC) is still controversial. This study aims to evaluate the efficacy of preoperative TACE on resectable HCC.MethodsPubmed, SCI, Medline, EMBASE, Cochrane Datebase, CNKI were searched. The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials’ data were reviewed by meta-analysis using the random effects model or fixed effect model by heterogeneity. The outcomes were expressed as odds ratio (OR) with 95% confidence intervals (CIs).ResultsA total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14 (95% CI = 0.90–1.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35 (95% CI = 1.07–1.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59 (95% CI = 0.46–0.77, P < 0.0001).ConclusionThe present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate. More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion. More... »

PAGES

532-536

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10330-013-1249-0

DOI

http://dx.doi.org/10.1007/s10330-013-1249-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043267861


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.412632.0", 
          "name": [
            "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yu", 
        "givenName": "Tingting", 
        "id": "sg:person.015137475351.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015137475351.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.412632.0", 
          "name": [
            "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Ximing", 
        "id": "sg:person.012737265611.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012737265611.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.412632.0", 
          "name": [
            "Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Biao", 
        "id": "sg:person.016252703331.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016252703331.65"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/pl00013185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027712879", 
          "https://doi.org/10.1007/pl00013185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-16037-0_4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001279187", 
          "https://doi.org/10.1007/978-3-642-16037-0_4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10330-004-0164-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001728316", 
          "https://doi.org/10.1007/s10330-004-0164-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00268-007-9245-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047164448", 
          "https://doi.org/10.1007/s00268-007-9245-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00268-003-6817-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052211696", 
          "https://doi.org/10.1007/s00268-003-6817-y"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-11", 
    "datePublishedReg": "2013-11-01", 
    "description": "ObjectiveThe efficacy of preoperative transarterial chemoembolization (TACE) for hepatectomy on hepatocelluar carcinoma (HCC) is still controversial. This study aims to evaluate the efficacy of preoperative TACE on resectable HCC.MethodsPubmed, SCI, Medline, EMBASE, Cochrane Datebase, CNKI were searched. The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials\u2019 data were reviewed by meta-analysis using the random effects model or fixed effect model by heterogeneity. The outcomes were expressed as odds ratio (OR) with 95% confidence intervals (CIs).ResultsA total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14 (95% CI = 0.90\u20131.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35 (95% CI = 1.07\u20131.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59 (95% CI = 0.46\u20130.77, P < 0.0001).ConclusionThe present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate. More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10330-013-1249-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1032171", 
        "issn": [
          "2095-9621", 
          "1613-9089"
        ], 
        "name": "The Chinese-German Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "disease-free survival rates", 
      "non-TACE group", 
      "preoperative transarterial chemoembolization", 
      "overall survival rate", 
      "transarterial chemoembolization", 
      "TACE group", 
      "odds ratio", 
      "hepatocelluar carcinoma", 
      "survival rate", 
      "liver resection", 
      "relevant clinical trials", 
      "confidence intervals", 
      "effects model", 
      "random effects model", 
      "ResultsA total", 
      "clinical trials", 
      "computerized search", 
      "larger sample size", 
      "manual search", 
      "resection", 
      "sufficient evidence", 
      "trials", 
      "efficacy", 
      "present data", 
      "group", 
      "sample size", 
      "chemoembolization", 
      "EMBASE", 
      "patients", 
      "carcinoma", 
      "MEDLINE", 
      "hepatectomy", 
      "CNKI", 
      "MethodsPubMed", 
      "rate", 
      "current conclusions", 
      "outcomes", 
      "treatment", 
      "total", 
      "study", 
      "SCI", 
      "conclusion", 
      "search", 
      "intervals", 
      "ratio", 
      "evidence", 
      "data", 
      "differences", 
      "cases", 
      "heterogeneity", 
      "literature", 
      "bibliography", 
      "model", 
      "article", 
      "size", 
      "resectable HCC", 
      "Cochrane Datebase", 
      "Datebase", 
      "preoperative TACE group", 
      "non-preoperative TACE group", 
      "ConclusionThe present data"
    ], 
    "name": "TACE combined with liver resection versus liver resection alone in the treatment of resectable HCC: a meta-analysis", 
    "pagination": "532-536", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043267861"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10330-013-1249-0"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10330-013-1249-0", 
      "https://app.dimensions.ai/details/publication/pub.1043267861"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:31", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_606.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10330-013-1249-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1249-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1249-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1249-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1249-0'


 

This table displays all metadata directly associated to this object as RDF triples.

153 TRIPLES      22 PREDICATES      91 URIs      78 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10330-013-1249-0 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N0d1f12094cc64358b52f4747251532b3
4 schema:citation sg:pub.10.1007/978-3-642-16037-0_4
5 sg:pub.10.1007/pl00013185
6 sg:pub.10.1007/s00268-003-6817-y
7 sg:pub.10.1007/s00268-007-9245-6
8 sg:pub.10.1007/s10330-004-0164-9
9 schema:datePublished 2013-11
10 schema:datePublishedReg 2013-11-01
11 schema:description ObjectiveThe efficacy of preoperative transarterial chemoembolization (TACE) for hepatectomy on hepatocelluar carcinoma (HCC) is still controversial. This study aims to evaluate the efficacy of preoperative TACE on resectable HCC.MethodsPubmed, SCI, Medline, EMBASE, Cochrane Datebase, CNKI were searched. The articles that focused on preoperative TACE for resectable HCC, published from 1990 to 2012, were collected by computerized search of literatures and manual search of bibliographies. The relevant clinical trials’ data were reviewed by meta-analysis using the random effects model or fixed effect model by heterogeneity. The outcomes were expressed as odds ratio (OR) with 95% confidence intervals (CIs).ResultsA total of 1347 patients were included in these 7 studies, the cases were divided into the preoperative TACE group and the non-preoperative TACE group, and there was no difference between the two groups in the 3-year disease-free survival rate, with an odds ratio of 1.14 (95% CI = 0.90–1.45, P = 0.27); the 5-year disease-free survival rate in the preoperative TACE group was better than that in the non-TACE group with an odds ratio of 1.35 (95% CI = 1.07–1.74, P = 0.02); the 5-year overall survival rate in the preoperative TACE group was higher than that in the non-TACE group with an odds ratio of 0.59 (95% CI = 0.46–0.77, P < 0.0001).ConclusionThe present data suggests that preoperative TACE has no different in improving the 3-year disease-free survival rate with non-TACE group for resectable HCC, while it can improve the 5-year disease-free survival rate and the 5-year overall survival rate. More randomized controlled trials using large sample size are needed to provide sufficient evidence to confirm current conclusion.
12 schema:genre article
13 schema:inLanguage en
14 schema:isAccessibleForFree false
15 schema:isPartOf N5ee85e3caccb45a0857b3a0cae65bff8
16 Ncb051f01e88442c8b0c2ba580e816246
17 sg:journal.1032171
18 schema:keywords CNKI
19 Cochrane Datebase
20 ConclusionThe present data
21 Datebase
22 EMBASE
23 MEDLINE
24 MethodsPubMed
25 ResultsA total
26 SCI
27 TACE group
28 article
29 bibliography
30 carcinoma
31 cases
32 chemoembolization
33 clinical trials
34 computerized search
35 conclusion
36 confidence intervals
37 current conclusions
38 data
39 differences
40 disease-free survival rates
41 effects model
42 efficacy
43 evidence
44 group
45 hepatectomy
46 hepatocelluar carcinoma
47 heterogeneity
48 intervals
49 larger sample size
50 literature
51 liver resection
52 manual search
53 model
54 non-TACE group
55 non-preoperative TACE group
56 odds ratio
57 outcomes
58 overall survival rate
59 patients
60 preoperative TACE group
61 preoperative transarterial chemoembolization
62 present data
63 random effects model
64 rate
65 ratio
66 relevant clinical trials
67 resectable HCC
68 resection
69 sample size
70 search
71 size
72 study
73 sufficient evidence
74 survival rate
75 total
76 transarterial chemoembolization
77 treatment
78 trials
79 schema:name TACE combined with liver resection versus liver resection alone in the treatment of resectable HCC: a meta-analysis
80 schema:pagination 532-536
81 schema:productId N5b24e96f034047c094f1c3eb1160b1b1
82 Nfea57758a85c4eba908b62354e5a15e3
83 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043267861
84 https://doi.org/10.1007/s10330-013-1249-0
85 schema:sdDatePublished 2022-01-01T18:31
86 schema:sdLicense https://scigraph.springernature.com/explorer/license/
87 schema:sdPublisher N5907e9827ade4172b91d4fefafc89bcd
88 schema:url https://doi.org/10.1007/s10330-013-1249-0
89 sgo:license sg:explorer/license/
90 sgo:sdDataset articles
91 rdf:type schema:ScholarlyArticle
92 N0d1f12094cc64358b52f4747251532b3 rdf:first sg:person.015137475351.88
93 rdf:rest N2b790f269b4947fc8db8006c67add1cb
94 N2b790f269b4947fc8db8006c67add1cb rdf:first sg:person.012737265611.78
95 rdf:rest N97b9a1338e5b4775838f9be10e768ff4
96 N5907e9827ade4172b91d4fefafc89bcd schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N5b24e96f034047c094f1c3eb1160b1b1 schema:name dimensions_id
99 schema:value pub.1043267861
100 rdf:type schema:PropertyValue
101 N5ee85e3caccb45a0857b3a0cae65bff8 schema:volumeNumber 12
102 rdf:type schema:PublicationVolume
103 N97b9a1338e5b4775838f9be10e768ff4 rdf:first sg:person.016252703331.65
104 rdf:rest rdf:nil
105 Ncb051f01e88442c8b0c2ba580e816246 schema:issueNumber 11
106 rdf:type schema:PublicationIssue
107 Nfea57758a85c4eba908b62354e5a15e3 schema:name doi
108 schema:value 10.1007/s10330-013-1249-0
109 rdf:type schema:PropertyValue
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
114 schema:name Clinical Sciences
115 rdf:type schema:DefinedTerm
116 sg:journal.1032171 schema:issn 1613-9089
117 2095-9621
118 schema:name The Chinese-German Journal of Clinical Oncology
119 schema:publisher Springer Nature
120 rdf:type schema:Periodical
121 sg:person.012737265611.78 schema:affiliation grid-institutes:grid.412632.0
122 schema:familyName Xu
123 schema:givenName Ximing
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012737265611.78
125 rdf:type schema:Person
126 sg:person.015137475351.88 schema:affiliation grid-institutes:grid.412632.0
127 schema:familyName Yu
128 schema:givenName Tingting
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015137475351.88
130 rdf:type schema:Person
131 sg:person.016252703331.65 schema:affiliation grid-institutes:grid.412632.0
132 schema:familyName Chen
133 schema:givenName Biao
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016252703331.65
135 rdf:type schema:Person
136 sg:pub.10.1007/978-3-642-16037-0_4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001279187
137 https://doi.org/10.1007/978-3-642-16037-0_4
138 rdf:type schema:CreativeWork
139 sg:pub.10.1007/pl00013185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027712879
140 https://doi.org/10.1007/pl00013185
141 rdf:type schema:CreativeWork
142 sg:pub.10.1007/s00268-003-6817-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052211696
143 https://doi.org/10.1007/s00268-003-6817-y
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s00268-007-9245-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047164448
146 https://doi.org/10.1007/s00268-007-9245-6
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/s10330-004-0164-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001728316
149 https://doi.org/10.1007/s10330-004-0164-9
150 rdf:type schema:CreativeWork
151 grid-institutes:grid.412632.0 schema:alternateName Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China
152 schema:name Center of Oncology, Renmin Hospital of Wuhan University, 430060, Wuhan, China
153 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...